Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm, Study of Elotuzumab, Selinexor, and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma

NCT05170789 is registered in ClinicalTrials.gov with Tulane University School of Medicine as lead sponsor.

NCT NCT05170789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05170789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm, Study of Elotuzumab, Selinexor, and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma
Lead sponsor
Tulane University School of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
April 27, 2022
Completion date
April 27, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapsed multiple myeloma